Taysha Gene Therapies (NASDAQ: TSHA) widens Q1 loss but affirms TSHA-102 BLA pathway

Rhea-AI Filing Summary

Taysha Gene Therapies reported first quarter 2026 results and progress on its Rett syndrome gene therapy TSHA-102. The company reaffirmed FDA alignment on its BLA pathway, including pivotal REVEAL trial design, endpoints and the potential to file based on a six-month interim analysis.

Research and development expenses were $33.8 million, up from $15.6 million a year earlier, reflecting BLA-enabling PPQ manufacturing and higher clinical spending on the REVEAL and ASPIRE trials. General and administrative expenses were $9.7 million, compared with $8.2 million.

Taysha reported a net loss of $42.4 million, or $0.12 per share, versus a $21.5 million loss, or $0.08 per share, in the prior-year quarter. The company ended March 31, 2026 with $276.6 million in cash and cash equivalents and expects this to fund planned operating expenses into 2028.

Positive

• Regulatory alignment and pivotal progress: The company reaffirmed FDA alignment on the TSHA-102 BLA pathway, including pivotal trial design and endpoints, and is dosing patients in the REVEAL and ASPIRE trials with plans to complete dosing in both by Q2 2026.
• Cash runway into 2028: Taysha reported $276.6 million in cash and cash equivalents as of March 31, 2026 and expects current resources to fund planned operating expenses into 2028, supporting completion of key development milestones.

Negative

• None.

Insights

Biotech and earnings analyst

Strong TSHA-102 progress and solid cash runway offset higher losses.

Taysha Gene Therapies highlighted continued advancement of TSHA-102 for Rett syndrome, including reaffirmed FDA alignment on its BLA pathway and ongoing pivotal REVEAL and ASPIRE trials. The company also began a BLA-enabling PPQ manufacturing campaign, with completion expected in Q4 2026.

Operating expenses rose as development intensified. Research and development reached $33.8M and general and administrative was $9.7M, producing a quarterly net loss of $42.4M or $0.12 per share. Revenue was zero versus $2.3M in the prior-year quarter as collaboration or other income streams tapered.

Despite higher spending, cash and cash equivalents of $276.6M as of March 31, 2026 are expected to fund planned operations into 2028. For investors, the key variables are successful completion of REVEAL and ASPIRE dosing in Q2 2026 and the quality of the upcoming Part A data readout supporting a future BLA filing.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Key Figures

Research and development expenses: $33.8 million General and administrative expenses: $9.7 million Net loss: $42.4 million +5 more

8 metrics

Research and development expenses $33.8 million Three months ended March 31, 2026

General and administrative expenses $9.7 million Three months ended March 31, 2026

Net loss $42.4 million Three months ended March 31, 2026, $0.12 per share

Revenue $0 Three months ended March 31, 2026 vs $2.3M in 2025

Cash and cash equivalents $276.6 million As of March 31, 2026; expected to fund operations into 2028

Total operating expenses $43.5 million Three months ended March 31, 2026

Total assets $300.4 million Balance sheet as of March 31, 2026

Stockholders’ equity $211.9 million Balance sheet as of March 31, 2026

Key Terms

Biologics License Application (BLA), PPQ campaign, Breakthrough Therapy, Regenerative Medicine Advanced Therapy, +2 more

6 terms

Biologics License Application (BLA) regulatory

"reaffirmed alignment with the FDA on our pathway to a BLA filing"

A biologics license application (BLA) is a formal request to a government agency seeking approval to sell a biological medicine, such as vaccines or gene therapies, in the market. It is similar to a detailed report that proves the product is safe, effective, and manufactured properly. For investors, a BLA signifies a critical step toward commercial availability, often impacting a company's valuation and market prospects.

PPQ campaign technical

"Initiated BLA-enabling PPQ campaign for TSHA-102 in April 2026"

Breakthrough Therapy regulatory

"TSHA-102 has received Breakthrough Therapy, Regenerative Medicine Advanced Therapy"

A breakthrough therapy is a regulatory designation granted to an experimental drug or treatment when early clinical evidence indicates it could offer a substantial improvement over existing options for a serious or life‑threatening condition. For investors it matters because the label brings faster, more intensive interaction with regulators and can shorten development and review time—like a VIP fast‑track toward potential approval, reducing time and risk before a product can reach the market.

Regenerative Medicine Advanced Therapy regulatory

"received Breakthrough Therapy, Regenerative Medicine Advanced Therapy, Fast Track"

Regenerative Medicine Advanced Therapy (RMAT) is a U.S. regulatory designation for cell, gene, and tissue‑based therapies intended to treat serious or life‑threatening conditions; it gives developers a “fast lane” with more frequent agency interaction and eligibility for accelerated review pathways. For investors, an RMAT label signals that a therapy may reach market faster and face less regulatory uncertainty than a standard program, which can raise the potential value and reduce timeline risk—though it is not a guarantee of approval.

Fast Track regulatory

"Regenerative Medicine Advanced Therapy, Fast Track and Orphan Drug and Rare Pediatric Disease designations"

A fast track designation is a regulatory label that speeds up the review and communication between a drug developer and regulators for treatments addressing serious illnesses or unmet medical needs. For investors, it matters because it can shorten development time and reduce regulatory delays—like getting a VIP lane at the airport—raising the chance of earlier market access and potential revenue, though it does not guarantee approval.

Orphan Drug designation regulatory

"has received Breakthrough Therapy, Regenerative Medicine Advanced Therapy, Fast Track and Orphan Drug and Rare Pediatric Disease designations"

Orphan drug designation is a special status given to medicines developed to treat rare diseases affecting only a small number of people. This status often provides benefits like faster approval processes and financial incentives, making it more attractive for companies to develop these drugs. For investors, it signals potential for exclusive market rights and reduced competition, which can impact the drug’s profitability.

Earnings Snapshot

Revenue: $0 · Guidance included

Q1 2026

Revenue $0 from $2.3M in Q1 2025

Net loss $42.4M vs $21.5M in Q1 2025

R&D expenses $33.8M vs $15.6M in Q1 2025

Cash and cash equivalents $276.6M as of March 31, 2026

Guidance

The company expects its current cash resources to fund planned operating expenses into 2028.

Understanding 8-K Material Events →

false 0001806310 0001806310 2026-05-06 2026-05-06

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 6, 2026

Taysha Gene Therapies, Inc.

(Exact name of registrant as specified in its Charter)

Delaware		001-39536		84-3199512
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

3000 Pegasus Park Drive, Suite 1430 Dallas, Texas		75247
(Address of Principal Executive Offices)		(Zip Code)

(214) 612-0000

(Registrant’s Telephone Number, Including Area Code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.00001 par value		TSHA		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On May 6, 2026, Taysha Gene Therapies, Inc. reported financial results for the quarter ended March 31, 2026, and recent business highlights. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference.

The information in this Item 2.02 of this Current Report on Form 8-K (including Exhibit 99.1) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Press Release, dated May 6, 2026.
104		Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

				Taysha Gene Therapies, Inc.
Dated: May 6, 2026				By:		/s/ Kamran Alam
						Kamran Alam
						Chief Financial Officer

Exhibit 99.1

Taysha Gene Therapies Reports First Quarter 2026 Financial Results and Provides Corporate Update

Reaffirmed FDA alignment on TSHA-102 BLA pathway, including pivotal trial design, endpoints and potential to submit for approval based on REVEAL pivotal trial 6-month interim analysis, following recent breakthrough therapy Type B meeting

Further advanced dosing in the REVEAL pivotal trial, with enrollment in the ASPIRE trial ongoing across multiple sites; on track to complete dosing in REVEAL and ASPIRE in Q2 2026

Maintained favorable tolerability profile with no treatment-related SAEs or DLTs in REVEAL Phase 1/2 and REVEAL pivotal trials as of May 2026 data cutoff; plan to present longer-term safety and efficacy data from Part A of REVEAL Phase 1/2 trials in Q2 2026

Initiated BLA-enabling PPQ campaign for TSHA-102 in April 2026; completion expected in Q4 2026

Conference call and webcast today at 8:30 AM ET

Dallas – May 6, 2026 – Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today reported financial results for the first quarter ended March 31, 2026, and provided a corporate update.

“We continued to execute our clinical development strategy for TSHA-102 and recently reaffirmed alignment with the FDA on our pathway to a BLA filing, including trial design, endpoints and the potential to submit for approval based on the six-month interim analysis from the REVEAL pivotal trial,” said Sean P. Nolan, Chairman and Chief Executive Officer of Taysha. “We further advanced dosing in the REVEAL pivotal trial, with enrollment in the ASPIRE trial ongoing across multiple sites, and we remain on track to complete dosing in both trials this quarter. In parallel, we plan to report longer-term safety and efficacy data from Part A of our REVEAL Phase 1/2 trials in the second quarter of this year.”

Mr. Nolan continued, “Our pivotal development strategy is grounded in the rigor of our natural history analysis and Part A data collection and evaluation, with trial design, endpoints and statistical analyses developed based on discussions with the FDA. In our upcoming Part A data readout, we expect to report longer-term follow-up, including at least 12-month data from all 12 pediatric, adolescent and adult patients treated with TSHA-102. These results will include functional gains based on natural history-defined developmental milestones and additional skills and improvements that impact activities of daily living. We look forward to sharing this data as we continue to demonstrate the differentiated opportunity for TSHA-102 to deliver meaningful benefit to a broad population of patients with Rett syndrome who continue to face high unmet medical need.”

Recent Corporate and TSHA-102 Program Highlights

• Reaffirmed FDA Alignment on Planned BLA Submission Pathway for TSHA-102. Following a recent initial breakthrough therapy Type B multidisciplinary meeting with the U.S. Food and Drug Administration (FDA), Taysha reaffirmed alignment on the planned pathway to a Biologics License Application (BLA) submission for TSHA-102, including:

• Pivotal trial design and endpoints

• BLA submission scenarios, including the potential to submit for approval based on the six-month interim analysis from the REVEAL pivotal trial

• Further Advanced Dosing in REVEAL Pivotal Trial, with Multiple Patients Dosed Across Multiple Clinical Trial Sites. The single-arm, open-label trial is evaluating a single intrathecal (IT) administration of high dose TSHA-102 (1x10¹⁵ total vector genomes (vg)) in 15 females between the ages of 6 and <22 years in the developmental plateau population of Rett syndrome. The primary endpoint will assess response rate, defined as the percentage of patients who gain or regain ≥one of the 28 natural history-defined developmental milestones, with each patient serving as their own control. Standardized milestone assessments will be administered and captured on video at pre- and post-treatment timepoints, with determination of milestone gain/regain upon video-evidence review by independent, blinded central raters based on prespecified definitions of achievement for each milestone. The study includes a six-month interim analysis that may serve as the basis for BLA submission.

• Enrollment in ASPIRE Trial is Ongoing Across Multiple Clinical Trial Sites. The ASPIRE safety-focused trial is designed to support a planned BLA submission to enable broad labeling of TSHA-102 for patients aged ≥2 years with Rett syndrome. Taysha is enrolling three females with Rett syndrome, aged 2 to <4 years, to evaluate the safety and preliminary efficacy of a single IT administration of high dose TSHA-102 (1x10¹⁵ total vg), scaled to account for the lower brain volume in 2 to <4-year-olds. A minimum of three months of ASPIRE safety data will be included in the planned BLA submission, while efficacy in the 2 to <6-year-old population will be extrapolated from data collected in the REVEAL pivotal trial.

• TSHA-102 Continues to be Generally Well Tolerated. High dose (1x10¹⁵ total vg) and low dose (5.7x10¹⁴ total vg) TSHA-102 continue to be generally well tolerated with no treatment-related serious adverse events (SAEs) or dose-limiting toxicities (DLTs) in all patients treated in the REVEAL Phase 1/2 and REVEAL pivotal trials as of the May 2026 data cutoff.

• Initiated BLA-Enabling PPQ Campaign for TSHA-102 Using Commercial Manufacturing Process in April 2026. Following a Type C meeting in January 2026, the FDA endorsed the Company’s proposed Process Performance Qualification (PPQ) campaign strategy in support of the BLA submission, enabling the execution of the BLA-enabling PPQ campaign using the commercial manufacturing process. Initiating the PPQ campaign ensures Chemistry Manufacturing and Controls (CMC) activities remain aligned with clinical development timelines for the planned BLA submission.

• Peer-Reviewed Publication Further Validates Lumbar IT Dosing as a Safe, Effective and Minimally Invasive Approach to Deliver a Gene Therapy to the CNS. The publication titled “rAAV9 Vector Biodistribution in Nonhuman Primate Brain and Spinal Cord Following Lumbar Intrathecal Infusion” was published in Frontiers in Medicine – Gene and Cell Therapy (DOI: 10.3389/fmed.2026.1819594)

on April 28, 2026. The publication includes preclinical data previously presented at the 2025 International Rett Syndrome Foundation (IRSF) Rett Syndrome Scientific Meeting, demonstrating IT and direct-to-brain intra-cisterna magna (ICM) administration showed comparable, consistent and widespread biodistribution of AAV9 vector throughout the brain and spinal cord regions in non-human primates.

• Abstract Accepted for Presentation at Upcoming American Society of Gene and Cell Therapy (ASGCT) 2026 Annual Meeting. The poster titled “Superior expression of self-complementary AAV and comparable functionality of mini and full-length MECP2 support the design of TSHA-102 for Rett syndrome” will be presented on May 14, 2026, and highlights new preclinical in vitro data demonstrating that self-complementary AAV9 achieved significantly higher MeCP2 expression compared to single-stranded AAV9 in neuronal mouse cell models, and the comparable functionality of mini and full-length MECP2.

Anticipated Milestones

• Completion of dosing in the REVEAL pivotal trial is expected in the second quarter of 2026

• Completion of dosing in the ASPIRE trial is expected in the second quarter of 2026

• Update on longer-term safety and efficacy data from Part A of the REVEAL Phase 1/2 trials (n=12) is expected in the second quarter of 2026

• Completion of BLA-enabling PPQ campaign for TSHA-102 is expected in the fourth quarter of 2026

First Quarter 2026 Financial Highlights

Research and Development Expenses: Research and development expenses were $33.8 million for the three months ended March 31, 2026, compared to $15.6 million for the three months ended March 31, 2025. The $18.2 million increase was primarily driven by BLA-enabling PPQ manufacturing initiatives performed during the three months ended March 31, 2026, and higher clinical expenses from the REVEAL and ASPIRE trials. Compensation expenses, including non-cash stock-based compensation, also increased as a result of additional research and development headcount.

General and Administrative Expenses: General and administrative expenses were $9.7 million for the three months ended March 31, 2026, compared to $8.2 million for the three months ended March 31, 2025. The increase of $1.5 million was primarily due to higher compensation expenses, including non-cash stock-based compensation expense, and increases in consulting and professional fees, including commercial launch-readiness initiatives.

Net Loss: Net loss for the three months ended March 31, 2026, was $42.4 million, or $0.12 per share, compared to a net loss of $21.5 million, or $0.08 per share, for the three months ended March 31, 2025. 

Cash and Cash Equivalents: As of March 31, 2026, Taysha had $276.6 million in cash and cash equivalents. The Company expects that its current cash resources will be sufficient to fund planned operating expenses into 2028.

Conference Call and Webcast Information

Taysha management will host a live conference call and webcast today at 8:30 a.m. ET to review its financial and operating results and provide a corporate update. Participants may access the live webcast of the conference call by visiting Taysha’s website.

About TSHA-102

TSHA-102 is a self-complementary intrathecally delivered AAV9 investigational gene transfer therapy in clinical evaluation for Rett syndrome. Designed as a one-time treatment, TSHA-102 aims to address the genetic root cause of the disease by delivering a functional form of MECP2 to cells in the CNS. TSHA-102 utilizes a novel miRNA-Responsive Auto-Regulatory Element (miRARE) technology designed to mediate levels of MECP2 in the CNS on a cell-by-cell basis without risk of overexpression. TSHA-102 has received Breakthrough Therapy, Regenerative Medicine Advanced Therapy, Fast Track and Orphan Drug and Rare Pediatric Disease designations from the FDA, Orphan Drug designation from the European Commission and Innovative Licensing and Access Pathway designation from the Medicines and Healthcare products Regulatory Agency.

About Rett Syndrome

Rett syndrome is a rare neurodevelopmental disorder caused by mutations in the X-linked MECP2 gene encoding methyl CpG-binding protein 2 (MeCP2), which is essential for regulating neuronal and synaptic function in the brain. The disorder is characterized by loss of communication and hand function, slowing and/or regression of development, motor and respiratory impairment, seizures, intellectual disabilities and shortened life expectancy. Rett syndrome progression is divided into four key stages, beginning with early onset stagnation at 6 to 18 months of age followed by rapid regression, plateau and late motor deterioration. Rett syndrome primarily occurs in females and is one of the most common genetic causes of severe intellectual disability. Currently, there are no approved disease-modifying therapies that treat the genetic root cause of the disease. Rett syndrome caused by a pathogenic/likely pathogenic MECP2 mutation is estimated to affect between 15,000 and 20,000 patients in the U.S., EU, and U.K.

About Taysha Gene Therapies

Taysha Gene Therapies (Nasdaq: TSHA) is a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. Its lead clinical program TSHA-102 is in development for Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. With a singular focus on developing transformative medicines, Taysha aims to address severe unmet medical needs and dramatically improve the lives of patients and their caregivers. The Company’s management team has proven experience in gene therapy development and commercialization. Taysha leverages this experience, its manufacturing process and a clinically and commercially proven AAV9 capsid in an effort to rapidly translate treatments from bench to bedside. For more information, please visit www.tayshagtx.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipates,” “believes,” “expects,” “intends,” “projects,” “plans,” and “future” or similar expressions are intended to identify forward-looking statements. Forward-looking statements include, but are not limited to, statements concerning the potential of TSHA-102 and Taysha’s other product candidates to positively impact quality of life and alter the course of disease in the patients Taysha seeks to treat, Taysha’s research, development, regulatory and manufacturing plans for its product candidates, communications with the FDA, including with respect to the BLA for TSHA-102, the potential for Taysha’s product candidates to receive regulatory approval from the FDA or equivalent foreign regulatory agencies, and whether, if approved, these product candidates will be successfully distributed and marketed and the potential market opportunity for Taysha’s product candidates, and the ability of Taysha’s current cash resources to support planned operating expenses into 2028. Forward-looking statements are based on management’s current expectations and are subject to various risks and uncertainties that could cause actual results to differ materially and adversely from those expressed or implied by such forward-looking statements. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding Taysha’s business are described in detail in Taysha’s Securities and Exchange Commission (“SEC”) filings, including in our Annual Report on Form 10-K for the full-year ended December 31, 2025, which are available on the SEC’s website at www.sec.gov. Additional information will be made available in other filings that Taysha makes from time to time with the SEC. These forward-looking statements speak only as of the date hereof, and Taysha disclaims any obligation to update these statements except as may be required by law.

Taysha Gene Therapies, Inc.

Condensed Consolidated Statements of Operations

(in thousands, except share and per share data)

		For the Three Months Ended March 31,
		2026				2025
Revenue		$	—			$	2,302
Operating expenses:
Research and development			33,809				15,565
General and administrative			9,677				8,158
Total operating expenses			43,486				23,723
Loss from operations			(43,486	)			(21,421	)
Other income (expense):
Change in fair value of warrant liability			—				102
Change in fair value of term loan			(1,470	)			(1,530	)
Interest income			2,586				1,326
Interest expense			(9	)			(19	)
Other (income) expense			(31	)			13
Total other income (expense), net			1,076				(108	)
Net loss		$	(42,410	)		$	(21,529	)
Net loss per common share, basic and diluted		$	(0.12	)		$	(0.08	)
Weighted average common shares outstanding, basic and diluted			366,632,827				269,306,331

Taysha Gene Therapies, Inc.

Condensed Consolidated Balance Sheet Data

(in thousands, except share and per share data)

		March 31, 2026				December 31, 2025
ASSETS
Current assets:
Cash and cash equivalents		$	276,576			$	319,767
Restricted cash			449				449
Prepaid expenses and other current assets			5,225				4,431
Total current assets			282,250				324,647
Restricted cash			2,315				2,315
Property, plant and equipment, net			6,450				6,736
Operating lease right-of-use assets			9,155				9,439
Other non-current assets			181				183
Total assets		$	300,351			$	343,320
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable		$	4,564			$	6,275
Accrued expenses and other current liabilities			15,534				20,277
Total current liabilities			20,098				26,552
Term loan, net			48,961				50,106
Operating lease liability, net of current portion			17,766				18,172
Other non-current liabilities			1,582				1,552
Total liabilities			88,407				96,382
Stockholders’ equity
Common stock, $0.00001 par value per share; 700,000,000 shares authorized and 287,276,885 and 285,051,648 issued and outstanding as of March 31, 2026 and December 31, 2025, respectively			3				3
Additional paid-in capital			964,666				958,427
Accumulated other comprehensive income (loss)			985				(192	)
Accumulated deficit			(753,710	)			(711,300	)
Total stockholders’ equity			211,944				246,938
Total liabilities and stockholders’ equity		$	300,351			$	343,320

Company Contact:

Hayleigh Collins

Senior Director, Corporate Communications and Investor Relations

Taysha Gene Therapies, Inc.

hcollins@tayshagtx.com

Media Contact:

Carolyn Hawley

Inizio Evoke

Carolyn.hawley@inizioevoke.com

FAQ

How did Taysha Gene Therapies (TSHA) perform financially in Q1 2026?

Taysha reported a net loss of $42.4 million, or $0.12 per share, for Q1 2026. This compares with a net loss of $21.5 million, or $0.08 per share, in the prior-year quarter as R&D and G&A expenses increased with advancing programs.

What were Taysha Gene Therapies (TSHA) research and development costs in Q1 2026?

Research and development expenses were $33.8 million for the quarter ended March 31, 2026. This rose from $15.6 million a year earlier, mainly due to BLA-enabling PPQ manufacturing work and higher clinical costs for the REVEAL and ASPIRE TSHA-102 trials.

What is Taysha Gene Therapies’ (TSHA) cash position and runway after Q1 2026?

As of March 31, 2026, Taysha held $276.6 million in cash and cash equivalents. The company stated that these resources are expected to fund its planned operating expenses into 2028, supporting TSHA-102 clinical development and related manufacturing activities.

What regulatory progress did Taysha Gene Therapies (TSHA) report for TSHA-102?

Taysha reaffirmed FDA alignment on the BLA pathway for TSHA-102, covering pivotal trial design, endpoints and the potential to submit for approval based on a six-month interim analysis from the REVEAL pivotal trial, following a breakthrough therapy Type B meeting.

What upcoming TSHA-102 milestones did Taysha Gene Therapies (TSHA) highlight?

Taysha plans to complete dosing in the REVEAL pivotal and ASPIRE trials in Q2 2026 and present longer-term safety and efficacy data from Part A of the REVEAL Phase 1/2 trials, including at least 12-month follow-up for all 12 treated patients.

Did Taysha Gene Therapies (TSHA) report any revenue in Q1 2026?

For the three months ended March 31, 2026, Taysha reported no revenue, compared with $2.3 million in the same period of 2025. The business remains focused on advancing TSHA-102 for Rett syndrome rather than generating product sales at this stage.

Filing Exhibits & Attachments

4 documents

Press Releases

• EX-99.1 EX-99.1 69.8 KB

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA 3.1 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE 17.6 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE 11.0 KB